XENOGEN IVIS-200 SMALL ANIMAL IMAGING SYSTEM: CANCER

该子项目是利用由NIH/NCRR资助的共享仪器补助金提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是资助机构，不一定是研究者的机构。描述（由申请人提供）：体内生物发光和荧光成像开辟了新的研究途径，特别是在癌症研究和传染病领域。Xenogen IVIS-200生物光子成像系统是目前进行这种全动物成像研究的最先进的仪器。本申请申请资金用于购买Xenogen IVIS-200成像系统，以资助美国国立卫生研究院资助的一个由14名列出的研究癌症和传染病的研究人员组成的核心小组的研究项目。这些研究人员使用Xenogen系统将占仪器时间的90%以上。目前在整个马里兰大学系统中没有具有可比成像能力的仪器。IVIS-200将被安置在Howard Hall中心的动物生物安全2级设施中，比较医学项目将为该仪器提供新装修的实验室空间。此外，比较医学项目还将资助一名具有博士学位的兽医，负责监督仪器的操作、维护和新用户的培训。这项资助的首席研究员Louis DeTolla是马里兰大学医学院比较医学主任和兽医资源主任，他特别适合管理这一仪器，为从事动物研究项目的众多研究人员提供服务。马里兰大学医学院的机构动物护理和使用委员会将作为该仪器的安全操作和所有列出的用户公平获得的内部咨询委员会。为现场技术支持和维修提供持续服务合同的资金将由Greenebaum癌症中心提供。癌症中心的网络开发办公室还将生成一个基于html的仪器预约系统，以促进远程时间分配，并提供仪器使用的中央记录，以确保公平访问。其中两个用户（Martin, Winkles）已经有了使用Xenogen生物光子成像系统的实际经验，并且已经用这些系统为他们的研究项目生成了初步数据。由于Xenogen IVIS-200的可用性，马里兰大学医学院的研究将大大加强，特别是在Greenebaum癌症中心和中大西洋地区生物防御和新发传染病卓越中心。

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): In vivo bioluminescence and fluorescence imaging has opened new research avenues, particularly in the fields of cancer research and infectious disease. The Xenogen IVIS-200 biophotonic imaging system is currently the state-of-the-art instrument for conducting such whole animal imaging studies. This application requests funding to purchase a Xenogen IVIS-200 imaging system to benefit the NIH-funded research projects of a core group of 14 listed investigators who are studying both cancer and infectious disease. Use of the Xenogen system by these investigators will account for more than 90% of instrument time. No instrument with comparable imaging capability currently exists in the entire University System of Maryland. The IVIS-200 will be housed in the centrally-located Animal Biosafety Level 2 facility of Howard Hall, and the Program in Comparative Medicine will provide newly-renovated laboratory space for the instrument. In addition, the Program in Comparative Medicine will provide funding for the salary of a Ph.D.-educated, faculty-appointed veterinarian to oversee instrument operation, maintenance and the training of new users. The Principal Investigator of this grant, Louis DeTolla, is the Director of Comparative Medicine and the Chief of Veterinary Resources at the University of Maryland Medical School, and is particularly well-suited to manage this instrument for the benefit of a wide range of investigators with animal research projects. The Institutional Animal Care and Use Committee of the University of Maryland School of Medicine will serve as an internal advisory board for the safe operation of the instrument and equitable access to all listed users. Funding to provide a continuing service contract for on-site technical support and repairs will be supplied by the Greenebaum Cancer Center. The web development office of the Cancer Center will also generate an HTML-based instrument reservation system to facilitate remote time allocation and provide a central record of instrument usage to ensure equitable access. Two of the users (Martin, Winkles) already have practical experience using Xenogen biophotonic imaging systems and have generated preliminary data on their research projects with these systems. Research at the University of Maryland School of Medicine will be greatly enhanced by the availability of a Xenogen IVIS-200, particularly within the Greenebaum Cancer Center and the Mid-Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Disease.